William Fodor - 29 Dec 2021 Form 4 Insider Report for Biostage, Inc. (HRGN)

Reporting relationship: Chief Scientific Officer
Issuer ticker: HRGN
Reported as of: 29 Dec 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Jan 2022, 18:02:33 UTC
Source filing: View source filing
Reporting owner signature: /s/ Chad Porter, by power of attorney

Key filing fact

William Fodor filed Form 4 for Biostage, Inc. (HRGN) on 03 Jan 2022.

Key facts

This page summarizes William Fodor's Form 4 filing for Biostage, Inc. (HRGN).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 03 Jan 2022, 18:02.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BSTG transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +196,103
Change %
Price: $0.000000
Shares after: 196,103
Date: 29 Dec 2021
Ownership: Direct
Underlying class: Common Stock, par value $0.01 per share
Underlying amount: 196,103
Exercise price: $2.30
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Subject to continued employment or service through the applicable vesting dates, these shares vest in four equal amounts on each of the grant date and each anniversary of the grant date.

SEC remarks

This form has been signed under power of attorney.